Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidathapolur (V), Muthukur (M), SPSR Nellore -524 346, Andhra Pradesh, India.
Research Article
World Journal of Advanced Research and Reviews, 2023, 18(03), 993-1002
Received on 16 April 2023; revised on 26 May 2023; accepted on 28 May 2023
The present study was undertaken with an aim to formulate develop and evaluate Trimetazidine HCL extended release matrix tablets using different polymers as release retarding agent. Pre formulation study was done initially and results directed for the further course of formulation. Based on Pre formulation studies different batches of Trimetazidine HCL were prepared using selected excipients. Powders were evaluated for tests Angle of repose, Bulk density, tapped density, compressibility index, and Hausner ratio before being punched as tablets. It was concluded that the tablets of batch F9 had considerable swelling behaviors and in vitro drug release. Percentage drug release in 8 hr is 80.77. It was observed that tablets of batch F9 followed the Huguchi release profiles. From the results and discussion it is concluded that formulation of Extended release matrix tablet of HCL containing HPMC K-15 (19.44%) and Hyper mellose (19.44%), Ethyl cellulose (19.44%) batch F9 can be taken as an ideal or optimized formulation Extended release matrix tablet for 8 hour release as it fulfills the requirements for extended release matrix tablet.
Trimetazidine HCL; HPMC K-15; Hypermellose; Ethyl cellulose
Preview Article PDF
Penabaka Venugopalaiah, KP Benidicts Prem Prakash, Yerikala Ramesh and M Alagusundaram. Formulation and evaluation of extended-release tablets of trimetazidine HCL. World Journal of Advanced Research and Reviews, 2023, 18(3), 993-1002. Article DOI: https://doi.org/10.30574/wjarr.2023.18.3.1003